期刊文献+

肌萎缩侧索硬化症患者ALSFRS-R评分与生存时间相关性分析 被引量:4

ALSFRS-R score predicts survival time in ALS
下载PDF
导出
摘要 目的:探讨肌萎缩侧索硬化症功能评分量表(amyotrophic lateral sclerosis functional rating scale revised,ALSFRS-R)及线性变化率(⊿FS)与生存时间相关性。方法:应用2000年世界神经病学联盟修订的El Escorial诊断标准分析64例肌萎缩侧索硬化症(amyotrophic lateral sclerosis,ALS)患者临床资料,予以ALSFRS-R评分及线性变化率(⊿FS),应用Kaplan–Meier法观察从起病至气管切开或死亡的生存曲线,以中位数分组并用Log-rank法检验,两组曲线不同。应用Cox比例风险模型,多因素分析法调整参数:性别、发病年龄、起病病程、用力肺活量(forced vital capacity,FVC)。结果:随访64例ALS患者,失访8人,56人气管切开或死亡,男∶女=2.7∶1。应用Log-rank法检验两组曲线P<0.05,有统计学意义。应用Cox比例风险模型ALSFRS-R评分(HR:0.87,95%CI:0.82~0.93,P<0.01),ALSFRS-R率(HR:5.52,95%CI:3.13~9.71,P<0.01)。结论:ALSFRS-R评分及⊿FS对患者预后有预测价值。 Objective: To study the amyotrophic lateral sclerosis functional rating scale revised(ALSFRS-R) and its progression rate of ALSFRS-R correlation with survival time.Methods:Application of 2000 word Union of Neurology El Escorial diagnostic criteria retrospectively analyzed 64 case of amyotrophic lateral sclerosis clinical date,be ALSFRS-R score and the progress rate(⊿FS)and Kaplan-Meier analysis was used from onset to tracheostomy or death,the median group and Log-rank analysis was used to estimate the difference between two groups.Application of Cox proportional hazards model,adjust the parameters of multi-factor analysis: sex,age,onset duration,forced vital capacity(FVC).Results:Total 64 ALS patient were followed,8 lost,56 with incision of tracheal or death,M∶F=2.7∶1,the average survival time of 3.5 years.Log-rank analysis of two groups was statistically significant.Application of Cox proportional hazards model ALSFRS-R(HR:0.87,95%CI:0.82-0.93,P 〈 0.01),⊿FS(HR:5.52,95%CI:3.13-9.71,P 〈 0.01).Conclusion:ALSFRS-R and ⊿FS predicting the prognosis of patients.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第2期244-247,共4页 Journal of Nanjing Medical University(Natural Sciences)
关键词 肌萎缩侧索硬化症 ALSFRS-R ⊿FS生存时间 amyotrophic lateral sclerosis ALSFRS-R ⊿FS survival time
  • 相关文献

参考文献17

  • 1Czaplinski A, Yen AA, Simpson EP, et al. Predictability of disease progression in amyotrophic lateral sclerosis [J].nuscle Nerve, 2006,34(6):702-708. 被引量:1
  • 2Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study [J]. Neurology, 2002,59 (1) : 99-103. 被引量:1
  • 3Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis [J]. Neurology ,2003,61 (4): 456-464. 被引量:1
  • 4Chio A, Mutani R, Mora G. Prognosis in amyotrophic lateral sclerosis: a population-based study [J]. Neurology,2003, 61(12) : 1826-1827. 被引量:1
  • 5Caroscio JT, Mulvihill MN, Sterling R,et al. Amyotrophic lateral sclerosis. Its natural history [J]. Neurologic Clinics, 1987,5 (1) : 1-8. 被引量:1
  • 6Kaufmann P, Levy G, Thompson JL, et al.The ALSFRSr predicts survival time in an ALS clinic population [J]. Neurology, 2005,64( 1 ) :38-43. 被引量:1
  • 7Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS [J]. Neurology, 2006,66(2):265-267. 被引量:1
  • 8Kollewe K,Mauss U,Krampfl K,et al. ALSFRS-R score and its ratio: A useful predictor for ALS-progression [J]. Neurol Sci, 2008,275 (1-2) : 69-73. 被引量:1
  • 9Jesse MC, Nancy S, Errol M, et al. The ALSFRS-R:a revised AKS functional rating scale that incorporates assessments of respiratory function [J]. Neurol Sci, 1999,169 (1-2) : 13-21. 被引量:1
  • 10Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis [J]. Amyotroph Lateral Scler Other Mot Neuron Disord , 2000, 1 (5) : 293-299. 被引量:1

二级参考文献17

  • 1Magnus T, Beck M, Giess R, et al. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve ,2002,25:709-714. 被引量:1
  • 2Kimura F, Fujimura C, Ishida S , et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology, 2006,66 : 265 -267. 被引量:1
  • 3Kaufmann P, Levy G, Thompson JL, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology, 2005,64 : 38-43. 被引量:1
  • 4Miller RG, Moore DH 2 nd, Gelinas DF, et al. Phase Ⅲ randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology,2001,56:843-848. 被引量:1
  • 5Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiamate in amyotrophic lateral sclerosis. Neurology, 2003,61:456-464. 被引量:1
  • 6Yuen E, Olney R. Longitudinal study of fibre density and motor unit estimates in patients with amytrophic lateral sclerosis. Neurology, 1997,49:573-578. 被引量:1
  • 7Cedarbaum JM, Stambler N, Malta E , et al. The ALSFRS-R : a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group ( phase Ⅲ ). J Neurol Sci, 1999,169 : 13-21. 被引量:1
  • 8Traynor B J, Zhang H, Shefner JM , et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology,2004,63: 1933-1935. 被引量:1
  • 9Brooks BR, Miller RG, Swash M , et al. E1 Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord ,2000,1:293- 299. 被引量:1
  • 10Armon C, Graves MC, Moses D , et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve, 2000,23:874-882. 被引量:1

共引文献7

同被引文献18

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部